These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 31293021

  • 1. The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial.
    Darand M, Darabi Z, Yari Z, Hedayati M, Shahrbaf MA, Khoncheh A, Hosseini-Ahangar B, Alavian SM, Hekmatdoost A.
    Phytother Res; 2019 Sep; 33(9):2369-2377. PubMed ID: 31293021
    [Abstract] [Full Text] [Related]

  • 2. Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial.
    Darand M, Darabi Z, Yari Z, Saadati S, Hedayati M, Khoncheh A, Hosseini-Ahangar B, Alavian SM, Hekmatdoost A.
    Complement Ther Med; 2019 Jun; 44():204-209. PubMed ID: 31126557
    [Abstract] [Full Text] [Related]

  • 3. The effect of nigella sativa supplementation on cardiometabolic outcomes in patients with non-alcoholic fatty liver: A randomized double-blind, placebo-controlled trial.
    Rashidmayvan M, Vandyousefi S, Barati M, Salamat S, Ghodrat S, Khorasanchi M, Jahan-Mihan A, Nattagh-Eshtivani E, Mohammadshahi M.
    Complement Ther Clin Pract; 2022 Aug; 48():101598. PubMed ID: 35567872
    [Abstract] [Full Text] [Related]

  • 4. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F, Adibi P, Hekmatdoost A.
    Br J Nutr; 2015 Sep 14; 114(5):796-803. PubMed ID: 26234526
    [Abstract] [Full Text] [Related]

  • 5. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease.
    Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, Poustchi H, Hedayati M, Aghajanpoor-Pasha M, Sadeghi A, Hekmatdoost A.
    Eur J Clin Nutr; 2019 Mar 14; 73(3):441-449. PubMed ID: 30610213
    [Abstract] [Full Text] [Related]

  • 6. The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trial.
    Zamani N, Shams M, Nimrouzi M, Zarshenas MM, Abolhasani Foroughi A, Fallahzadeh Abarghooei E, Fattahi MR.
    Complement Ther Med; 2018 Dec 14; 41():118-123. PubMed ID: 30477827
    [Abstract] [Full Text] [Related]

  • 7. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial.
    Cheraghpour M, Imani H, Ommi S, Alavian SM, Karimi-Shahrbabak E, Hedayati M, Yari Z, Hekmatdoost A.
    Phytother Res; 2019 Aug 14; 33(8):2118-2125. PubMed ID: 31264313
    [Abstract] [Full Text] [Related]

  • 8. Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial.
    Khonche A, Huseini HF, Gholamian M, Mohtashami R, Nabati F, Kianbakht S.
    J Ethnopharmacol; 2019 Apr 24; 234():106-111. PubMed ID: 30639231
    [Abstract] [Full Text] [Related]

  • 9. The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Ghanbari P, Raiesi D, Alboebadi R, Zarejavid A, Dianati M, Razmi H, Bazyar H.
    BMC Complement Med Ther; 2024 May 16; 24(1):192. PubMed ID: 38755622
    [Abstract] [Full Text] [Related]

  • 10. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial.
    Hosseinabadi S, Rafraf M, Asghari S, Asghari-Jafarabadi M, Vojouhi S.
    Complement Ther Med; 2020 Mar 16; 49():102290. PubMed ID: 32147076
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A.
    Nutr Res; 2014 Oct 16; 34(10):837-43. PubMed ID: 25311610
    [Abstract] [Full Text] [Related]

  • 13. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG.
    BMC Med; 2016 Jun 29; 14():92. PubMed ID: 27353492
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial.
    Mahdavi R, Namazi N, Alizadeh M, Farajnia S.
    Food Funct; 2015 Jun 29; 6(6):2041-8. PubMed ID: 26029855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.